- Home
- ALLO
as 07-26-2024 4:00pm EST
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Upcoming Earnings Alert:
Get ready for potential market movements as Allogene Therapeutics Inc. ALLO prepares to release earnings report on 31 Jul 2024.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 576.2M | IPO Year: | 2018 |
| Target Price: | $10.51 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $5.78 | Next Earning Date: | 07-31-2024 |
| Revenue: | $65,000 | Revenue Growth: | -48.00% |
| Revenue Growth (this year): | -46.75% | Revenue Growth (next year): | 8170.08% |
Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MESSEMER DEBORAH M. | ALLO | Director | Jun 18 '24 | Sell | $2.28 | 18,641 | $42,488.43 | 166,765 | SEC Form 4 |
| Humer Franz B | ALLO | Director | May 30 '24 | Sell | $2.34 | 11,200 | $26,181.12 | 255,253 | SEC Form 4 |
| Belldegrun Arie | ALLO | Director | May 16 '24 | Buy | $2.90 | 1,724,137 | $4,999,997.30 | 1,724,137 | SEC Form 4 |
| Parker Geoffrey M. | ALLO | CHIEF FINANCIAL OFFICER | Jan 30 '24 | Buy | $3.60 | 190 | $683.05 | 819,590 | SEC Form 4 |
| MESSEMER DEBORAH M. | ALLO | Director | Dec 18 '23 | Sell | $2.70 | 18,640 | $50,316.82 | 62,456 | SEC Form 4 |
Latest Allogene Therapeutics Inc. News
ALLO Breaking Stock News: Dive into ALLO Ticker-Specific Updates for Smart Investing
GlobeNewswire
25 days ago
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
Simply Wall St.
a month ago
With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns
Insider Monkey
a month ago
Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock?
GlobeNewswire
a month ago
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
Zacks
a month ago
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
MT Newswires
2 months ago
Piper Sandler Starts Allogene Therapeutics With Overweight Rating, $11 Price Target
TipRanks
2 months ago
Insiders Pour Millions Into These 2 ‘Strong Buy’ Stocks
GlobeNewswire
2 months ago
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
Compare ALLO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLO Allogene Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.